MEDNAX, Inc., together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services. The company also provides maternal-fetal care, including inpatient and office-based clinical care to expectant mothers and their unborn babies through maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians consisting of maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers, and genetic counselors. In addition, its pediatric cardiology care services comprise inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through pediatric cardiologist subspecialists and other related clinical professionals. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, and pediatric surgeons, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. Additionally, it provides radiology and teleradiology services. As of December 31, 2017, the company's network consisted of approximately 4,075 affiliated physicians. MEDNAX, Inc. was founded in 1979 and is based in Sunrise, Florida.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Hospitals
Sub-IndustryHealth Care Services
SectorMedical
Current SymbolNYSE:MD
Previous SymbolNYSE:PDX
CUSIP58502B10
Phone954-384-0175
Debt
Debt-to-Equity Ratio0.67
Current Ratio1.43
Quick Ratio1.43
Price-To-Earnings
Trailing P/E Ratio12.29
Forward P/E Ratio11.03
P/E Growth1.07
Sales & Book Value
Annual Sales$3.46 billion
Price / Sales1.00
Cash Flow$4.2087 per share
Price / Cash Flow9.20
Book Value$32.74 per share
Price / Book1.18
Profitability
EPS (Most Recent Fiscal Year)$3.15
Net Income$320.37 million
Net Margins9.50%
Return on Equity10.45%
Return on Assets5.53%
Miscellaneous
Employees7,675
Outstanding Shares89,420,000
Market Cap$3.52 billion
OptionableOptionable
MEDNAX (NYSE:MD) Frequently Asked Questions
What is MEDNAX's stock symbol?
MEDNAX trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD."
How were MEDNAX's earnings last quarter?
MEDNAX Inc (NYSE:MD) issued its earnings results on Thursday, November, 1st. The company reported $0.94 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.97 by $0.03. The firm earned $896.60 million during the quarter, compared to analyst estimates of $908.15 million. MEDNAX had a net margin of 9.50% and a return on equity of 10.45%. The business's quarterly revenue was up 3.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.87 earnings per share. View MEDNAX's Earnings History.
When is MEDNAX's next earnings date?
What guidance has MEDNAX issued on next quarter's earnings?
MEDNAX updated its fourth quarter earnings guidance on Thursday, November, 1st. The company provided EPS guidance of $0.87-0.95 for the period, compared to the Thomson Reuters consensus estimate of $1.01. MEDNAX also updated its Q4 2018 guidance to $0.87-0.95 EPS.
What price target have analysts set for MD?
14 Wall Street analysts have issued 1-year price objectives for MEDNAX's shares. Their forecasts range from $37.00 to $62.00. On average, they expect MEDNAX's share price to reach $50.5714 in the next year. This suggests a possible upside of 30.5% from the stock's current price. View Analyst Price Targets for MEDNAX.
What is the consensus analysts' recommendation for MEDNAX?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEDNAX in the last year. There are currently 1 sell rating, 9 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for MEDNAX.
Has MEDNAX been receiving favorable news coverage?
News coverage about MD stock has trended somewhat positive recently, according to InfoTrie. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. MEDNAX earned a news sentiment score of 1.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future.
Who are some of MEDNAX's key competitors?
Some companies that are related to MEDNAX include Encompass Health (EHC), Select Medical (SEM), Magellan Health (MGLN), Animalcare Group (ANCR), Capitol Health (CAJ), Healthscope (HSO), Medical Facilities (DR), Primary Health Care (PRY), Ramsay Health Care Limited Fully Paid Ord. Shrs (RHC), Spine Injury Solutions (SPIN), SunLink Health Systems (SSY) and THC Biomed Intl (THC).
Who are MEDNAX's key executives?
MEDNAX's management team includes the folowing people:
- Dr. Roger J. Medel, Co-Founder, CEO & Director (Age 71)
- Mr. Joseph M. Calabro, Pres & COO (Age 57)
- Ms. Vivian Lopez-Blanco, CFO & Treasurer (Age 60)
- Mr. Dominic J. Andreano, Sr. VP, Gen. Counsel & Sec. (Age 49)
- Mr. David A. Clark, Pres of Mednax National Medical Group Division (Age 51)
Who are MEDNAX's major shareholders?
MEDNAX's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.34%), Vanguard Group Inc. (9.26%), Pzena Investment Management LLC (3.64%), Credit Suisse AG (2.74%), Dimensional Fund Advisors LP (2.50%) and FMR LLC (2.14%). Company insiders that own MEDNAX stock include Cesar L Alvarez, David A Clark, Dominic J Andreano, Enrique Sosa, John C Pepia, Joseph M Calabro, Manuel Kadre, Md Carlo A Waldemar, Md Pascal J Goldschmidt, Paul G Gabos, Robert Irwin Valliant and Vivian Lopez-Blanco. View Institutional Ownership Trends for MEDNAX.
Which major investors are selling MEDNAX stock?
MD stock was sold by a variety of institutional investors in the last quarter, including Thompson Siegel & Walmsley LLC, Credit Suisse AG, Wells Fargo & Company MN, Toronto Dominion Bank, Morgan Stanley, JPMorgan Chase & Co., JPMorgan Chase & Co. and Wedge Capital Management L L P NC. Company insiders that have sold MEDNAX company stock in the last year include David A Clark, Dominic J Andreano, John C Pepia, Joseph M Calabro and Vivian Lopez-Blanco. View Insider Buying and Selling for MEDNAX.
Which major investors are buying MEDNAX stock?
MD stock was purchased by a variety of institutional investors in the last quarter, including Pzena Investment Management LLC, Bank of New York Mellon Corp, Point72 Asset Management L.P., Renaissance Technologies LLC, Vanguard Group Inc., Hsbc Holdings PLC, Bank of Montreal Can and BlackRock Inc.. View Insider Buying and Selling for MEDNAX.
How do I buy shares of MEDNAX?
Shares of MD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MEDNAX's stock price today?
One share of MD stock can currently be purchased for approximately $38.75.
How big of a company is MEDNAX?
MEDNAX has a market capitalization of $3.52 billion and generates $3.46 billion in revenue each year. The company earns $320.37 million in net income (profit) each year or $3.15 on an earnings per share basis. MEDNAX employs 7,675 workers across the globe.
What is MEDNAX's official website?
How can I contact MEDNAX?
MEDNAX's mailing address is 1301 CONCORD TERRACE, SUNRISE FL, 33323. The company can be reached via phone at 954-384-0175 or via email at [email protected]
MarketBeat Community Rating for MEDNAX (NYSE MD)
MarketBeat's community ratings are surveys of what our community members think about MEDNAX and other stocks. Vote "Outperform" if you believe MD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MD will underperform the S&P 500 over the long term. You may vote once every thirty days.
